Antiproteinuric effect of cilnidipine in hypertensive japanese treated with renin-angiotensin-system inhibitors-A multicenter, open, randomized trial using 24-hour urine collection

Clinical and Experimental Hypertension

Volumn 32, Issue 6, 2010, Pages 400-405

  Miwa, Yoshikazu ^a   Tsuchihashi, Takuya ^b   Ohta, Yuko ^b   Tominaga, Mitsuhiro ^c   Kawano, Yuhei ^d   Sasaguri, Toshiyuki ^e   Ueno, Michio ^f   Matsuoka, Hiroaki ^g  

^a Sasaguri Hospital   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^c Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers   (Japan)

^d NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^g DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Cilnidipine; Hypertension; Proteinuria; Randomized trial; Renin angiotensin system (RAS) inhibitor

Indexed keywords

ALACEPRIL; AMLODIPINE; CANDESARTAN; CILNIDIPINE; ENALAPRIL; IMIDAPRIL; LOSARTAN; VALSARTAN;

ADULT; AGED; ARTERIOLE; ARTICLE; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; HUMAN; HYPERTENSION; JAPANESE; MEAN ARTERIAL PRESSURE; MORBIDITY; MORTALITY; MULTICENTER STUDY; PATIENT; PROTEIN URINE LEVEL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINE;

AMLODIPINE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; FEMALE; HUMANS; HYPERTENSION; JAPAN; MALE; PROTEINURIA; TREATMENT OUTCOME;

EID: 78049423503     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641961003667914     Document Type: Article

References (34)

1. Yudkin JS, Forrest RD, Jackson CA. Microalbuminuria as predictor of vascular disease in non-diabetic subjects. Islington Diabetes Survey. Lancet 1988;2:530-533.
2. Bigazzi R, Bianchi S, Baldari D, Compese VM. Microalbu-minuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998;16: 1325-1333.
3. Schrader J, Luders S, Kulschewski A, et al. Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study). J Hypertens 2006;24:541-548.
4. Irie F, Iso H, Sairenchi T, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int 2006;69:1264-1271.
5. Remuzzi G, Ruggenenti P, Benigni A. Understanding the nature of renal disease progression. Kidney Int 1997;51:2-15 (Review).
6. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephr-opathy. The Collaborative Study Group. N Engl J Med 1993;329: 1456-1462.
7. Brenner BM, Cooper ME, de Zeeuw D, et al. RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869.
8. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med.2001; 345:870-878.
9. Mancia G, De Backer G, Dominiczak A, et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-1187.
10. Chobanian AV, Bakris GL, Black HR, et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee.The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560-2572.
11. Guideline Subcommittee. Japanese society of hypertension guidelines for the management of hypertension (JSH 2004) Hypertens Res 2006;29(suppl):S1-S105.
12. Hirning LD, Fox AP, McCleskey EW, et al. Dominant role of N-type Ca2+ channels in evoked release of norepinephrine from sympathetic neurons. Science 1988;239:57-61.
13. Fogo AB. Glomerular hypertension, abnormal glomerular growth, and progression of renal diseases. Kidney Int Suppl 2000;75:S15-21 (Review).
14. DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997;77:75-197 (Review
15. Zhou X, Ono H, Ono Y, Frohlich ED. N-and L-type calcium channel antagonist improves glomerular dynamics, reverses severe nephrosclerosis, and inhibits apoptosis and proliferation in an l-NAME/SHR model. J Hypertens 2002;20:993-1000.
16. Konda T, Enomoto A, Matsushita J, Takahara A, Moriyama T. The N-and L-type calcium channel blocker cilnidipine suppresses renal injury in dahl rats fed a high-sucrose diet, an experimental model of metabolic syndrome. Nephron Physiol 2005;101:1-13.
17. Rose GW, Kanno Y, Ikebukuro H, et al. Cilnidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclero-sis. Hypertens Res 2001;24:377-383.
18. Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and amlodipine besilate with respect to proteinuria in hypertensive patients with renal diseases. Hypertens Res 2004; 27:379-385.
19. Fujita T, Ando K, Nishimura H, et al. Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Desease(CARTER) Study Investigators. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007;72:1543-1549.
20. Tsuchihashi T, Ueno M, Tominaga M, et al. Anti-proteinuric effect of an N-type calcium channel blocker, cilnidipine. Clin Exp Hypertens 2005;27:583-591.
21. Tochikubo O, Uneda S, Kaneko Y. Simple portable device for sampling a whole day's urine and its application to hypertensive outpatients. Hypertension 1983;5:270-274.
22. Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123: 754-762.
23. 2+ current recorded from the rabbit basilar artery. Circ Res 1990;67: 993-1006.
24. 2+ channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 1997;280:1184-1191.
25. 2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. Br J Pharmacol 1997;122:37-42.
26. Loutzenhiser R, Hayashi K, Epstein M. Divergent effects of KCl-induced depolarization on afferent and efferent arterioles. Am J Physiol 1989;257:F561-564.
27. 2+-channel blockade. J Hypertens 1998;16 (suppl 2):S182 (abstract).
28. Sugiura T, Imai E, Moriyama T, Horio M, Hori M. Calcium channel blockers inhibit proliferation and matrix production in rat mesangial cells: possible mechanism of suppression of AP-1 and CREB activities. Nephron 2000;85:71-80.
29. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30-48.
30. Mann JF, Schmieder RE, McQueen M, et al. ONTARGET investigators. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-553.
31. Minami J, Ishimitsu T, Kawano Y, Numabe A, Matsuoka H. Comparison of 24-hour blood pressure, heart rate, and autonomic nerve activity in hypertensive patients treated with cilnidipine or nifedipine retard. J Cardiovasc Pharmacol 1998;32:331-336.
32. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
33. Sarafidis PA, Khosla N, Bakris GL. Antihypertensive therapy in the presence of proteinuria. Am J Kidney Dis. 2007;49:12-26 (Review).
34. Ruggenenti P, Perna A, Remuzzi G; GISEN Group Investigators. Retarding progression of chronic renal disease: the neglected issue of residual proteinuria. Kidney Int 2003;63: 2254-2261.